Innogen unveiled its innovative journey in metabolic diseases, starting from the inception of GLP-1 science to global clinical development. The insight was shared during the DIA Global Annual Meeting 2026 in Philadelphia on June 22. The discussion took place at the China Town Hall session, where Innogen highlighted its progression from ground zero to successful advancement. This marked achievement signifies a significant milestone in the company's evolution towards combating metabolic diseases on an international scale.